New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:25 EDTRHT, NKE, CEMI, HALO, PFE, RIMM, WAG, TSPTOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Red Hat (RHT), up 5.4%... Nike (NKE), up 3%... ALSO HIGHER: Chembio Diagnostics (CEMI), up 20.7% after receiving FDA approval for its rapid HIV test... Halozyme (HALO), up 17.4% after entering a development collaboration with Pfizer (PFE)... Ameristar Casinos (ASCA), up 17% after agreeing to be acquired by Pinnacle Entertainment (PNK) for $26.50 per share... LOWER AFTER EARNINGS: Research in Motion (RIMM), down 16.3%... Walgreen (WAG), down 1.7%... ALSO LOWER: Transcept (TSPT), down 14.7% after Phase 2 trial of OCD drug misses primary endpoint.
News For RHT;NKE;CEMI;HALO;PFE;RIMM;WAG;TSPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
October 15, 2014
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
10:02 EDTNKEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:28 EDTNKENike upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
06:12 EDTNKENike's Converse sues rivals over 'copycat' design, NY Post reports
Converse, a unit of Nike (NKE), is suing rivals including Ralph Lauren (RL) and Tory Burch, alleging that shoemakers and retailers are copying its iconic design, the New York Post reports. Lawyers for Converse say "We welcome fair competition, but we do not believe companies have a right to copy the trademarked look." The lawsuit seeks unspecified damages and injunctions that would bar the production of the rival shoe models. Reference Link
October 14, 2014
17:16 EDTTSPTTranscept Pharmaceuticals declares special dividend of $12.79M, or 66c per share
Subscribe for More Information
11:23 EDTPFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
06:03 EDTWAGWalgreen implied volatility of 27 at lower end of index mean range
Subscribe for More Information
October 13, 2014
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
06:41 EDTWAGWalgreens to roll out Apple Pay on October 18, MacRumors reports
Walgreens (WAG) will begin rolling out Apple Pay (AAPL) on Saturday, October 18, according to a memo obtained by MacRumors. Reference Link
06:13 EDTWAGWalgreen implied volatility of 25 at lower end of index mean range
Subscribe for More Information
October 10, 2014
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
06:04 EDTWAGWalgreen implied volatility of 24 at lower end of index mean range
Subscribe for More Information
October 9, 2014
09:41 EDTNKEBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
06:10 EDTNKEStocks with implied volatility below IV index mean; NKE LULU
Subscribe for More Information
October 8, 2014
10:55 EDTPFELeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
08:09 EDTPFEPfizer presents LP2086 Phase 2 study data
Pfizer announced it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086, or rLP2086, with a licensed quadrivalent human papillomavirus vaccine at IDWeek 2014. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4. Prespecified noninferiority criteria were met for the bivalent rLP2086 antigens studied and three of the four antigens for HPV4. Primary immunogenicity endpoints, measured after the third dose, included geometric mean titers against HPV antigens in Groups 1 and 3 and human complement serum bactericidal assay GMTs against meningococcal group B disease test strains in Groups 1 and 2. Secondary immunogenicity endpoints included the rate of seroconversion to HPV antigens. Safety of bivalent rLP2086 was assessed after concomitant administration with HPV4 or saline. The prespecified noninferiority criteria were met for three of four HPV antigens and both meningococcal group B disease test strains. Seroconversion for all four HPV antigens was achieved by 99% or more of the subjects for the groups that received HPV4 concomitantly with bivalent rLP2086 or with saline. More local reactions occurred following administration of bivalent rLP2086 compared with saline but the incidence of these reactions did not increase with subsequent vaccine administration. The rates of local and systemic reactions were comparable when bivalent rLP2086 was given with HPV4 to bivalent rLP2086 given alone.
07:19 EDTPFECBI to hold a conference
Subscribe for More Information
07:18 EDTPFEInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
06:02 EDTWAGWalgreen implied volatility of 23 at lower end of index mean range
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use